Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:GNFTNASDAQ:LENZNYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.69+0.3%$4.00$3.21▼$8.06$882.87M0.64.47 million shs3.11 million shsGNFTGENFIT$3.61-6.0%$4.11$2.55▼$6.42$180.50M1.1510,510 shs22,737 shsLENZLENZ Therapeutics$30.18+0.2%$28.58$16.54▼$43.50$849.57M0.42190,320 shs1.29 million shsZYMEZymeworks$12.47+0.8%$12.18$8.32▼$17.70$867.63M1.17586,482 shs2.15 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx0.00%+3.65%-0.81%-24.85%-50.20%GNFTGENFIT0.00%-7.08%-17.58%+5.56%0.00%LENZLENZ Therapeutics0.00%+0.80%+3.04%+17.39%+74.55%ZYMEZymeworks0.00%-0.08%+6.86%+4.70%+46.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.3482 of 5 stars3.53.00.04.42.12.50.6GNFTGENFIT2.2352 of 5 stars3.54.00.00.02.70.00.0LENZLENZ Therapeutics1.302 of 5 stars3.60.00.00.02.00.80.0ZYMEZymeworks1.917 of 5 stars3.51.00.00.01.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$10.89195.09% UpsideGNFTGENFIT 3.00Buy$13.00260.11% UpsideLENZLENZ Therapeutics 3.17Buy$46.6054.41% UpsideZYMEZymeworks 2.90Moderate Buy$21.0068.40% UpsideCurrent Analyst Ratings BreakdownLatest GNFT, ARDX, ZYME, and LENZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ARDXArdelyxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/20/2025ZYMEZymeworksTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/20/2025ZYMEZymeworksTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M2.65N/AN/A$0.73 per share5.05GNFTGENFIT$76.77M2.35$0.07 per share51.61$1.50 per share2.41LENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/AZYMEZymeworks$93.38M9.29N/AN/A$6.63 per share1.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A11.90N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.77N/AN/AN/AN/A-23.74%-22.65%8/13/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)Latest GNFT, ARDX, ZYME, and LENZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.044.123.81GNFTGENFIT0.081.231.23LENZLENZ TherapeuticsN/A23.0923.09ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%GNFTGENFIT2.24%LENZLENZ Therapeutics54.32%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%GNFTGENFIT4.20%LENZLENZ Therapeutics6.90%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million227.77 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableLENZLENZ Therapeutics11028.15 million26.20 millionN/AZYMEZymeworks46069.58 million67.56 millionOptionableGNFT, ARDX, ZYME, and LENZ HeadlinesRecent News About These CompaniesZymeworks Amends Warrant Agreement with EcoR1 CapitalJune 27 at 4:59 PM | tipranks.comZYME - Zymeworks Inc Registered Shs Dividends - MorningstarJune 27 at 3:30 PM | morningstar.comMCompanies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In GrowthJune 25, 2025 | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus Price Target from BrokeragesJune 24, 2025 | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 21, 2025 | marketbeat.comAll You Need to Know About Zymeworks (ZYME) Rating Upgrade to BuyJune 20, 2025 | zacks.comRhumbline Advisers Has $985,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)June 20, 2025 | marketbeat.comDuncan Williams Asset Management LLC Buys Shares of 22,095 Zymeworks Inc. (NYSE:ZYME)June 19, 2025 | marketbeat.comZymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500June 18, 2025 | kalkinemedia.comKSG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME)June 17, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 147,184 Shares of Zymeworks Inc. (NYSE:ZYME)June 15, 2025 | marketbeat.comZymeworks (NYSE:ZYME) Shares Gap Down - Time to Sell?June 13, 2025 | marketbeat.comZymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)June 12, 2025 | seekingalpha.comBank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME)June 12, 2025 | marketbeat.comWellington Management Group LLP Decreases Position in Zymeworks Inc. (NYSE:ZYME)June 5, 2025 | marketbeat.comWall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?June 4, 2025 | zacks.comZymeworks’ zanidatamab gains approval in China for biliary tract cancerJune 2, 2025 | msn.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLCJune 2, 2025 | marketbeat.comVoloridge Investment Management LLC Buys Shares of 43,708 Zymeworks Inc. (NYSE:ZYME)May 31, 2025 | marketbeat.comRoche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestoneMay 30, 2025 | endpts.comEChina's NMPA Approves Zymeworks' Ziihera for HER2-High Biliary Tract CancerMay 30, 2025 | precisionmedicineonline.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNFT, ARDX, ZYME, and LENZ Company DescriptionsArdelyx NASDAQ:ARDX$3.69 +0.01 (+0.27%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.70 +0.00 (+0.14%) As of 06:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.GENFIT NASDAQ:GNFT$3.61 -0.23 (-5.99%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$2.76 -0.85 (-23.55%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.LENZ Therapeutics NASDAQ:LENZ$30.18 +0.07 (+0.23%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$29.80 -0.38 (-1.27%) As of 05:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Zymeworks NYSE:ZYME$12.47 +0.10 (+0.81%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$12.10 -0.37 (-2.97%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
